NCT03575234 - Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer | Biotech Hunter

Timeline

Start Date

July 1, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Human Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaStage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

IRX-2

Given SC

BIOLOGICAL

Nivolumab

Given IV

PROCEDURE

Surgery

Undergo surgery

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta